MC38-hCD47/hCLDN18.2/hHER3
Strain Information
Validation Data
Ⅰ.In vitro Expression of MC38-hCD47/hCLAUDIN18.2/hHER3 cell line
The human CD47 , human claudin18.2 and human HER3 protein expression in the MC38-hCD47/hCLAUDIN18.2/hHER3 cells were measured by Flow Cytometry.
Figure 1. The expression of hCD24 , hCLAUDIN18.2 and hHER3 in MC38-hCD47/hCLAUDIN18.2/hHER3 cell line
Ⅱ.Characterization of in vivo growth kinetics
To test the take rates, and the tumor growth characteristics of MC38-hCD47/hCLAUDIN18.2/hHER3 cell line, cells were subcutaneously inoculated into the C57BL/6 mice.
Figure 2. Tumor growth curve of MC38-hCD47/hCLAUDIN18.2/hHER3 syngeneic model
Figure 3. Body weight change of MC38-hCD47/hCLAUDIN18.2/hHER3 syngeneic model
Ⅲ.Expression of hCD47/hCLAUDIN18.2/hHER3 protein in tumors
To verify the human CD47 , human claudin18.2 and human HER3 protein expression, the tumors were dissected and separated for single cell suspension.
Figure 4. The expression of hCD47 , hCLAUDIN18.2 and hHER3 in humanized modified tumors by FACS
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
